[Therapeutic efficacy and general tolerability of 4-carbomethoxythiazolidine chlorohydrate in adult patients with hypersecretory bronchopulmonary diseases].
40 patients suffering from acute hypersecretive bronchopulmonary disorders were treated for a period of 6-9 days. They have been administered 4-carbomethoxythiazolidine both in capsules and in granular form at a dosage of 400 mg/day. At the beginning of the treatment with 4-carbomethoxythiazolidine (basal stage) after 3-4 days and at the end (final stage) the following clinic parameters have been registered: presence and quantity of the expectoration, difficulty in expectoration, signs of bronchial hypersecretion detectable by thorax auscultation, cough. At the basal and final stages the haematochemical parameters have been determinated such as: haemoglobin, azotemia, SGOT, SGPT, read corpuscles. They did not show individual or average variation over the values registered at the basal stage. At the end of the experiments collected data, biometric elaboration by Wilcoxon test has been carried out. The conclusive judgement on the efficacy of 4-carbomethoxythiazolidine, has been positive in 95% of the cases.
Campisi
U
U
Divisione Pneumologia A. Francaviglia, Ente Ospedialiero Ascoli Tomaselli, Catania.
Sciutto
L
L
Patti
S
S
D001982:Bronchial Diseases / Q000188:drug therapy*; D005100:Expectorants / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D013844:Thiazoles / Q000627:therapeutic use*
D005100:Expectorants; D013844:Thiazoles; C070586:4-carbomethoxythiazoline
Attività terapeutica e tollerabilità di 4-carbometossitiazolidina HCl in pazienti adulti con affezioni broncopolmonari ipersecretive.